 |
MorphoSys AG
MOR
|
1.75 |
- |
2.43 % |
$ 254 M |
Germany |
 |
Altimmune
ALT
|
7.76 K |
$ 3.47 |
3.89 % |
$ 306 M |
USA |
 |
I-Mab
IMAB
|
94.1 |
- |
- |
$ 866 M |
China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 |
- |
- |
$ 40.3 B |
USA |
 |
Genfit SA
GNFT
|
1.96 K |
- |
2.54 % |
$ 160 B |
France |
 |
Ascendis Pharma A/S
ASND
|
947 |
$ 219.83 |
-0.92 % |
$ 5 B |
Danmark |
 |
Midatech Pharma plc
MTP
|
137 |
- |
-18.52 % |
$ 27.3 M |
Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K |
- |
-1.52 % |
$ 24.7 M |
USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
65.5 |
- |
- |
$ 26.5 M |
USA |
 |
Aeterna Zentaris
AEZS
|
7.87 |
- |
5.93 % |
$ 314 M |
Canada |
 |
AgeX Therapeutics
AGE
|
0.099 |
- |
-10.17 % |
$ 12.2 K |
USA |
 |
Acorda Therapeutics
ACOR
|
0.142 |
- |
-24.86 % |
$ 820 K |
USA |
 |
Albireo Pharma
ALBO
|
13.3 |
- |
-0.23 % |
$ 916 M |
USA |
 |
Acasti Pharma
ACST
|
0.203 |
- |
4.01 % |
$ 150 M |
Canada |
 |
Институт стволовых клеток человека
ISKJ
|
2.61 |
- |
- |
- |
Russia |
 |
Grifols, S.A.
GRFS
|
1.71 |
$ 7.69 |
1.39 % |
$ 6.83 B |
Spain |
 |
Adverum Biotechnologies
ADVM
|
76.4 |
- |
- |
$ 86.2 M |
USA |
 |
Acer Therapeutics
ACER
|
25.8 |
- |
2.71 % |
$ 14 M |
USA |
 |
Advaxis
ADXS
|
144 |
- |
-9.65 % |
$ 45.9 M |
USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
10.4 |
$ 0.6 |
-2.83 % |
$ 6.87 M |
Israel |
 |
Ayala Pharmaceuticals
AYLA
|
11.2 |
- |
- |
$ 7.46 M |
Israel |
 |
Cullinan Management
CGEM
|
35.1 |
$ 13.01 |
2.12 % |
$ 784 M |
USA |
 |
BioDelivery Sciences International
BDSI
|
1.85 |
- |
-4.8 % |
$ 255 M |
USA |
 |
Heron Therapeutics
HRTX
|
1.28 |
$ 0.8 |
2.29 % |
$ 133 M |
USA |
 |
BeiGene, Ltd.
BGNE
|
66.4 |
- |
0.49 % |
$ 251 B |
Cayman-islands |
 |
Calithera Biosciences
CALA
|
98.5 |
- |
-10.95 % |
$ 876 K |
USA |
 |
Cara Therapeutics
CARA
|
2.58 |
- |
-3.03 % |
$ 260 M |
USA |
 |
ChemoCentryx
CCXI
|
0.0564 |
- |
- |
$ 3.74 B |
USA |
 |
Incyte Corporation
INCY
|
3.79 |
$ 91.13 |
0.38 % |
$ 17.8 B |
USA |
 |
Checkpoint Therapeutics
CKPT
|
3.91 K |
- |
- |
$ 169 M |
USA |
 |
Clovis Oncology
CLVS
|
1.55 |
- |
-7.23 % |
$ 13 M |
USA |
 |
Inovio Pharmaceuticals
INO
|
265 |
$ 1.6 |
0.95 % |
$ 35.5 M |
USA |
 |
Aeglea BioTherapeutics
AGLE
|
489 |
- |
- |
$ 1.01 B |
USA |
 |
CureVac N.V.
CVAC
|
281 |
- |
- |
$ 867 M |
Germany |
 |
Denali Therapeutics
DNLI
|
7.68 |
$ 21.15 |
4.86 % |
$ 3.48 B |
USA |
 |
Inventiva S.A.
IVA
|
128 |
$ 6.07 |
5.02 % |
$ 138 M |
France |
 |
Arbutus Biopharma Corporation
ABUS
|
24.5 |
$ 4.3 |
1.3 % |
$ 714 M |
Canada |
 |
AIkido Pharma
AIKI
|
1.08 |
- |
1.93 % |
$ 17.4 M |
USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
130 |
- |
-5.98 % |
$ 34.1 M |
USA |
 |
Deciphera Pharmaceuticals
DCPH
|
7.34 |
- |
- |
$ 2.18 B |
USA |
 |
Cardiff Oncology
CRDF
|
196 |
$ 1.8 |
0.08 % |
$ 120 M |
USA |